Trial Profile
A Phase II, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of KRP-AB1102 Compared With Placebo for 4- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 10 Jun 2016 New trial record